 The aim of this study is to test whether the attention-enhancing effects of low-dose nicotine can be enhanced by the drug galantamine, FDA-approved for the treatment of Alzheimers disease. This proof-of-principle study is performed in healthy non-smokers and involves two single exposures to a nicotine patch 7 mg24 hrs and two single exposures to galantamine 4 mg. The dose of galantamine is substantially lower than the clinical dose range of 16-24 mgday. The hypothesis is that performance-enhancing effects of nicotine are greater in the presence of this low dose of galantamine. 